Navigation Links
Ovarian Tumors May Develop Years After Fertility Therapy
Date:10/27/2011

THURSDAY, Oct. 27 (HealthDay News) -- Women who undergo ovarian stimulation to produce extra eggs for in-vitro fertilization (IVF) are at increased risk for a type of growth known as "borderline ovarian tumors," new research suggests.

Borderline ovarian tumors are typically not aggressive, according to the U.S. National Cancer Institute. Even if the tumor does spread, the vast majority of women survive borderline ovarian tumors.

Even so, treating borderline ovarian tumors can require extensive surgery, explained lead researcher Flora van Leeuwen, head of the epidemiology department in The Netherlands Cancer Institute.

For the study, researchers examined data from over 19,000 infertile women in the Netherlands who underwent ovarian stimulation prior to IVF and about 6,000 infertile women who did not undergo IVF.

After 15 years of follow-up, the women who underwent ovarian stimulation were four times more likely to develop a borderline ovarian tumor, according to the findings published in the Oct. 27 online edition of the journal Human Reproduction.

"Our data clearly show that ovarian stimulation for IVF is associated with an increased risk of borderline ovarian tumors and this risk remains elevated up to more than 15 years after the first cycle of treatment," van Leeuwen explained in a journal news release.

Overall, however, the number of women developing any sort of ovarian tumor was low. The cumulative risk in the general population of an ovarian malignancy for women under age 55 in the Netherlands is 0.45 percent. For women who undergo IVF, it's 0.71 percent, "with the increase being due to borderline tumors of the ovary," van Leeuwen added.

The low number of women in the study who developed ovarian malignancies prevented the researchers from determining if repeated IVF cycles increased the risk of ovarian malignancies. They noted in the news release that they are expanding their study population to examine that issue.

"If we find out that women who receive several IVF cycles or large doses of ovarian-stimulating drugs are at a greater risk of ovarian cancer, then these women would need to be informed about these risks when continuing IVF treatment and possibly advised to discontinue treatment after three to six cycles (depending on which number of cycles would be associated with the high risk of ovarian malignancies)," van Leeuwen noted.

The International Federation of Fertility Societies (IFFS) issued a statement in response to the new study findings. In it, general secretary of the IFFS, Richard Kennedy of Coventry, England, said: "Over the last decade, several reports have considered the long-term risks of ovarian stimulation practiced as part of the IVF process. These reports have been generally reassuring in terms of risk of ovarian cancer."

However, Kennedy added, "This new research has highlighted the presence of an increased risk of borderline tumors . . . and has once again posed a question about the long-term risks of ovarian stimulation further confounded by the known underlying risks for these patients. The IFFS remains of the view that the long-term risks are low but calls for continued vigilance through reporting of long-term outcomes with international collaboration."

More information

The American Cancer Society has more about ovarian cancer.

-- Robert Preidt

SOURCES: Human Reproduction, news release, Oct. 26, 2011; International Federation of Fertility Societies, statement, Oct. 26, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Linking of mutations in 12 genes to ovarian cancer may lead to more effective prevention
2. Terry Fox Research Institute aims to change diagnosis and management of ovarian cancer worldwide
3. Mutant Gene That Ups Risk for Ovarian Cancer May Aid Survival
4. Early detection is key in the fight against ovarian cancer
5. Moffitt researchers find possible key to preventing chemotherapy resistance in ovarian cancer
6. New hybrid imaging device shows promise in spotting hard-to-detect ovarian cancer
7. FDA clears biomarker test for ovarian cancer
8. Key function of mutation in hereditary breast and ovarian cancer gene discovered
9. Plants could pave the way for new ovarian cancer treatments
10. Trial Drug Shows Preliminary Promise Against Ovarian Cancer
11. Blood Antibody May Signal Start of Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Ovarian Tumors May Develop Years After Fertility Therapy
(Date:5/24/2017)... ... May 24, 2017 , ... Technique, technique, technique – with a ... lifting weights for strength training and exercise or simply lifting heavy objects, advises Dr. ... position is everything,” Dr. Chang says. “Improper technique in lifting anything heavy or an ...
(Date:5/23/2017)... New York City (PRWEB) , ... May 23, ... ... Record (EHR), Population Health and Clinical Integration company, announced today that its ... Patient-Centered Medical Home (PCMH) 2017 Prevalidation. NCQA recently introduced PCMH 2017 standards ...
(Date:5/23/2017)... ... May 23, 2017 , ... Allegheny Health Network and the ... Center for Women’s Behavioral Health at West Penn Hospital , a unique facility ... suffering from pregnancy-related depression. Construction of the Center is underway with a scheduled ...
(Date:5/23/2017)... ... 2017 , ... Cambridge, MA, May 23, 2017—Total costs per ... a Workers Compensation Research Institute (WCRI) study, a contrast from the increases of ... Benchmarks, 17th Edition looks at indemnity and medical payments for workers’ compensation ...
(Date:5/23/2017)... ... May 23, 2017 , ... i2i ... 2017 Best in KLAS category winner, has named Daniel P. Bullington as chief ... enhance its technology platform and product offerings,” says Justin Neece, president. “Daniel is ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)... 18, 2017  Two Bayer U.S. Pharmaceutical leaders received ... its recent 28 th Woman of the ... showcases HBA,s longstanding mission of furthering the advancement and ... Cindy Powell-Steffen , senior director of brand ... and Libby Howe , a regional business manager ...
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based ... to treat Parkinson,s disease (PD), has enrolled the first patient ... randomized, controlled, multicenter study involving patients with PD and taking ... over a 9-to-12-month period. The first stage is open label ... Participating sites include Denver , ...
(Date:5/10/2017)... May 10, 2017 Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended April 1, 2017 ... $1.84 increased 666.7% compared to the prior year period ... in a significant gain, while non-GAAP diluted EPS of ... or 3.8% in constant currency terms.  Excluding the effects ...
Breaking Medicine Technology: